Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

@article{Verma2016EffectOE,
  title={Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?},
  author={Subodh Verma and Ankit Garg and Andrew T Yan and Anup Kumar Gupta and Mohammed A Al-Omran and Andre Sabongui and Hwee Teoh and Cyril David Mazer and Kim A Connelly},
  journal={Diabetes care},
  year={2016},
  volume={39 12},
  pages={e212-e213}
}
Amid the excitement over the results of the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial (1), the potential mechanisms through which empagliflozin produced a rapid and profound reduction in hospitalization for heart failure and cardiovascular (CV) death in subjects with type 2 diabetes remain entirely unexplained. Importantly, the effects of empagliflozin on objective measures of cardiac structure and function are… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS
20 Citations
6 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…